-
Most Popular
Biotech Stocks
Biotech is defined as using technology to change, manipulate, and harness biological processes in order to fulfill a medical need. The applications of biotech are endless and range from genetically modifying foods to creating vaccines. During the height of the coronavirus pandemic, companies like Moderna and BioNTech utilized biotech to create life-saving vaccines that were distributed across the globe.
7 Recession-Resistant Stocks to Hold Onto for Dear Life in 2024
These seven recession-resistant stocks offer stability and potential growth even in challenging economic conditions.
3 Promising Biotech Stocks for the Long-Term: August 2024
Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Here are just a few.
The 3 Best Healthcare Stocks to Buy in August 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Other industries you might be interested in
Recent Biotech Stocks Articles
Amgen, Inc (AMGN) – Amgen Stock Is a Powerhouse
Biotechs such as Amgen stock have been riding high for more than a month. AMGN in particular looks promising for new money.
Novavax, Inc.: NVAX Stock Gets Gutted — Can It Still Double?
Novavax, Inc. (NASDAQ:NVAX) is leading the biotech charge downward today on dismal earnings that left investors questioning the bull case.
The iShares Nasdaq Biotechnology Index (ETF) (IBB) — It’s Make-or-Break Time
While the intermediate-term trend remains intact for the IBB etf, earnings season for large biotech companies could be make-or-break.
The iShares Nasdaq Biotechnology Index (ETF) (IBB): Gravity Calls!
Active investors and traders should look to play the iShares Nasdaq Biotechnology Index (ETF) (IBB) to the short side until the picture changes.
ABBV Stock: Could AbbVie Inc’s Gamble on Stemcentrx Pay Off?
Stemcentrx's acquisition does little to alleviate the risk of the potential decrease in sales once Humira loses patent protection.
Is Pfizer Inc. Finally Safe To Buy Again? (PFE)
A first-quarter earnings and revenue beat has investors excited once again with formerly beat-down Pfizer Inc. Is now the time to buy PFE?
iShares Nasdaq Biotechnology Index (ETF) (IBB): Nibble on the Long Side
Biotech stocks, after some prolonged weakness, are starting to show promising relative and absolute strength. That means opportunity in the IBB.
Trade of the Day: Nautilus, Inc. (NYSE:NLS)
Nautilus (NLS) shares fell 3.7% Monday on no news, offering traders a phenomenal entry point.
Opko Health Inc.: FDA Denial Won’t Kill OPK
The approval delay of Rayaldee, Opko Health's new billion-dollar drug, won't hurt its market performance. OPK is a high-risk/high-reward stock.
Gilead Sciences, Inc.: GILD Could Squeeze the Bears From Here
Gilead Sciences enjoyed a rally Monday along with the rest of the biotech sector. This breakout could be followed up by a short squeeze in GILD stock.
The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is a Buy, But Not for Long
The iShares Nasdaq Biotechnology ETF (IBB) has yet to pull off something that other parts of the market have -- and that spells opportunity in IBB.
2 Drug Stocks To Buy For Safe Dividends And 20% Gains
With all the talk on the campaign trail about drug costs, it's safe to say the pharmaceutical industry is under siege. But these drug stocks are solid buys
Johnson & Johnson: How Healthy Is JNJ Stock?
Johnson & Johnson (JNJ) stock has long been a mainstay of many investors' healthcare holdings. But is JNJ's future still bright?
Pfizer Inc. Stock: A Good Buy While the Pharma Industry Is Down (PFE)
Between a planned merger with Allergan and a strong pipeline of drugs, PFE stock is a solid choice at a great price.
4 Healthcare Stocks on Shaky Ground – MRK LLY AZN BMY
Biotechnology stocks have broken down, and certain pharmaceutical stocks are now following suit. Could Merck and other pharmas suffer more downside?
The iShares Nasdaq Biotechnology Index (ETF) (IBB) Is Ready to Bounce!
The IBB ETF of biotech stocks has reached support levels that could spark a better bounce. Active investors should take notice.
Clovis Oncology (CLVS) Knocked Out By FDA Inquiry
Clovis Oncology Inc suffered a massive setback to its lung cancer treatment program, erasing years of gains made by CLVS stock.
